(baseline CSDD score ≥ 18) were selected and compared (n = 6 for each group), differences were more definite. The main difference was in the 'cyclic functions' category. Significant differences were not observed among secondary outcome measures. The number of treatment-related adverse-events (AE) did not differ between groups (p=0.83) and no serious treatment-related AE were observed. Conclusion: The use of escitalopram was well tolerated in depressive dementia patients, and it also reduced depressive symptoms faster that placebo in subjects with definite major depression. Future studies focusing on subjects with more severe levels of depression, and with more statistical power, will be needed.
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A comparative study of serum Tau protein and Aß levels on intestinal endotoxemia among Alzheimer's disease rats and in Chinese sample of Alzheimer's disease patients and healthy controls 
The General Hospital of The Chinese Armed Police Forces (CAPF) China
Abstract Objective: Early our animal experiments study showed that AD rats occurs intestinal endotoxemia (IETM), and with the increasing of endotoxin, the Tau protein and Aβ increased and promote the generation of AD. Study on the change of endotoxin Tau protein and Aβ levels on intestinal endotoxemia on Alzheimer's disease rats and in Chinese sample of Alzheimer's disease patients and healthy controls. Methods: The AD model of wistar rats were produced by injecting D-galactose and AlCl 3 for 90 days. From January 2014 to January 2015, 40 subjects were selected from Hospitals and Nursing Homes at Taiyuan City and Perking, and control group were from communities. Neurocognitive function was detected by neuropsychological tests with the Mini mental state examination (MMSE) and Alzheimer's disease assessment scale cognitive subscale (ADAS-cog); LPS level was detected by CE TAL; TNFα and Tau protein and Aβ levels were tested by ELISA. Results: Compared with the control group, the AD rats group had longer latency (P<0.05) and more error times (P<0.05) in Morris water maze test, and LPS, TNF-α and Tau protein and Aβ levels were increased (P<0.05). MMSE score in the patients with AD were significantly lower than the healthy elderly (P<0.01), ADASCog score in patients with AD were significantly higher than the healthy elderly (P <0.001); AD patients' and healthy controls LPS, TNF-α, Tau protein and Aβ were significantly higher than the healthy elderly (P<0.01). Conclusion: AD rats and patients with AD and healthy controls were all accompanied intestinal endotoxemia and that may be a new risk factors in the development in the process of happen of AD, Tau protein and Aβ role is unique, and is also proved a powerful evidence of Alzheimer's disease.
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Study on intestinal endotoxemia on learning memory ability and hippocampal gene expression of apoptosis of brain cell in Alzheimer's disease rats To investigate the effect of intestinal endotoxemia (IETM) on learning and memory ability in rats with Alzheimer's disease (AD) and its possible mechanisms. Methods: The AD model of wistar rats were produced by injecting D-galactose and AlCl 3 intraperitoneally for 90 days. Subsequently, learning and memory ability of the rats were evaluated by Morris water maze; the level of lipopolysaccharide (LPS) and tumor necrosis factor-α (TNF α ), IL-1 β , IL-10, TNF α , NO were determined by ELISA; the apoptosis of brain cell were detected by TUNEL. Results: The learning and memory ability of the rats were observed by Morris water maze. The results indicated that compared with the normal control, the learning and memory ability of model rats and AD rats is markedly decreased; LPS and IL-1 β , IL-10, TNF α , NO in blood in AD rats were increased (P<0.05); indicated that compared with the normal control, the incidence rate of the brain cell apoptosis of model rats and AD rats is markedly increased (P<0.01).
Conclusions:
The rat model of Alzheimer's disease is accompanied IETM and that apoptosis of hippocampus of brain cell may plays an important role in the development of AD. Key words: Alzheimer's disease; Intestinal endotoxemia; LPS; TNF-α; apoptosis of brain cell
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Alzheimer disease therapeutics candidate, SAK3 improves the cognitive functions through inhibition of amyloid beta accumulation in APP23 mice. (Ethyl 2', -pyridine]-3-carboxylates) (PCT/JP2013/051388). SAK3 stimulates T-type voltage-gated Ca 2+ channels (T-VGCC) in mouse cortical slices (Moriguchi et al., J Neurochem 2012; 121:44-53) . We also reported that SAK3 stimulates acetylcholine release and promotes longterm potentiation in mouse hippocampus (Neuroscience 2014 abstract 265.21). We here tested whether SAK3 reduced amyliod beta (1-42) accumulation in Alzheimer model (APP23) mice. APP23 mice aged 6 and 9 months were treated for two or three months with SAK3 (0.5mg/kg, p.o.) and measured amyliod beta (1-42) levels in both soluble and insoluble fractions from APP23 mouse cortex. The chronic administration significantly reduced the amyliod beta (1-42) levels. Consistent with the reduced amyliod beta (1-42) levels, the numbers of amyloid plaques assessed by thioflavin staining were significantly reduced by the chronic SAK3 treatment. Furthermore, the cognition assessed by novel object recognition task was improved by the chronic administration. Using LC/MS/MS system, we established high sensitivity quantification system in blood to obtain proof-of-concept of SAK3 safety in human. Taken together, the novel T-type calcium channel stimulator SAK3 restored cognition ability in APP23 mice and reduced the amyliod beta (1-42) accumulation/
